Kymera Therapeutics, Inc.
$86.20
The Read: Kymera’s stock has historically rallied about 6% when securing large cash reserves and advancing mid-stage trials despite earnings misses, showed modest gains on pipeline progress and FDA Fast Track news, but reacted mutedly to early KT-621 efficacy data.
Price
Overlays
Panel
KYMR
Hover to view data
No Data